{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:46:57Z","timestamp":1785916017868,"version":"3.56.0"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.phymed.2024.155505","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T08:15:34Z","timestamp":1709712934000},"page":"155505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["A promising therapy for fatty liver disease: PCSK9 inhibitors"],"prefix":"10.1016","volume":"128","author":[{"given":"Lizhu","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-505X","authenticated-orcid":false,"given":"Liuyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9921-0304","authenticated-orcid":false,"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2365-9177","authenticated-orcid":false,"given":"Yuan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2024.155505_bib0001","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2147\/TCRM.S144121","article-title":"Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9","volume":"13","author":"Adorni","year":"2017","journal-title":"Ther. Clin. Risk. Manage"},{"key":"10.1016\/j.phymed.2024.155505_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/nu12051440","article-title":"Naturally occurring PCSK9 inhibitors","volume":"12","author":"Adorni","year":"2020","journal-title":"Nutrients."},{"key":"10.1016\/j.phymed.2024.155505_bib0003","first-page":"1099","article-title":"Berberine: ins and outs of a nature-made PCSK9 inhibitor","volume":"21","author":"Ataei","year":"2022","journal-title":"EXCLI. J."},{"key":"10.1016\/j.phymed.2024.155505_bib0004","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bcp.13490","article-title":"Critical evaluation of causality assessment of herb-drug interactions in patients","volume":"84","author":"Awortwe","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0005","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1177\/2047487317724342","article-title":"PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans","volume":"24","author":"Baragetti","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.phymed.2024.155505_bib0006","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/1750-3841.13647","article-title":"Curcumin protects against intestinal origin endotoxemia in rat liver cirrhosis by targeting PCSK9","volume":"82","author":"Cai","year":"2017","journal-title":"J. Food Sci."},{"key":"10.1016\/j.phymed.2024.155505_bib0007","doi-asserted-by":"crossref","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"Canuel","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phymed.2024.155505_bib0008","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/jcb.27102","article-title":"Berberrubine and its analog, hydroxypropyl-berberrubine, regulate LDLR and PCSK9 expression via the ERK signal pathway to exert cholesterol-lowering effects in human hepatoma HepG2 cells","volume":"120","author":"Cao","year":"2019","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.phymed.2024.155505_bib0009","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1038\/s41598-018-24935-6","article-title":"Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network","volume":"8","author":"Chae","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phymed.2024.155505_bib0010","article-title":"Tanshinone IIA modulates low density lipoprotein uptake via down-regulation of PCSK9 gene expression in HepG2 Cells","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phymed.2024.155505_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/nu9020096","article-title":"Effects of natural products on fructose-induced nonalcoholic fatty liver disease (NAFLD)","volume":"9","author":"Chen","year":"2017","journal-title":"Nutrients."},{"key":"10.1016\/j.phymed.2024.155505_bib0012","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/jmf.2016.3877","article-title":"Ethanol extract of Capsella bursa-pastoris improves hepatic steatosis through inhibition of histone acetyltransferase activity","volume":"20","author":"Choi","year":"2017","journal-title":"J. Med. Food"},{"key":"10.1016\/j.phymed.2024.155505_bib0013","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-019-1267-z","article-title":"Interaction between phytotherapy and oral anticancer agents: prospective study and literature review","volume":"36","author":"Clairet","year":"2019","journal-title":"Med. Oncol."},{"key":"10.1016\/j.phymed.2024.155505_bib0014","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phymed.2024.155505_bib0015","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 Induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phymed.2024.155505_bib0016","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacl.2017.06.005","article-title":"A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease","volume":"11","author":"Di Filippo","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phymed.2024.155505_bib0017","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1074\/jbc.M114.597229","article-title":"Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1alpha protein expression through the ubiquitin-proteasome degradation pathway","volume":"290","author":"Dong","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0018","article-title":"Sirtuin 6-A Key Regulator of Hepatic Lipid Metabolism and Liver Health","volume":"12","author":"Dong","year":"2023","journal-title":"CellsCells"},{"key":"10.1016\/j.phymed.2024.155505_bib0019","first-page":"505","article-title":"Expression of fatty acid synthase in nonalcoholic fatty liver disease","volume":"3","author":"Dorn","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.phymed.2024.155505_bib0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000479734","article-title":"Oral Administration of CardioAid and Lunasin Alleviates Liver Damage in a High-Fat Diet Nonalcoholic Steatohepatitis Model","volume":"96","author":"Drori","year":"2017","journal-title":"DigestionDigestion"},{"key":"10.1016\/j.phymed.2024.155505_bib0021","article-title":"Hepatic and circulating levels of PCSK9 in morbidly obese patients: relation with severity of liver steatosis","volume":"1865","author":"Emma","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.phymed.2024.155505_bib0022","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phymed.2024.155505_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104994","article-title":"Structure-activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents","volume":"113","author":"Fan","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0024","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.lfs.2007.08.043","article-title":"Tanshinone IIA inhibits atherosclerotic plaque formation by down-regulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet","volume":"81","author":"Fang","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.phymed.2024.155505_bib0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2018.08.036","article-title":"Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: an open-label extension of the ODYSSEY program","volume":"278","author":"Farnier","year":"2018","journal-title":"AtherosclerosisAtherosclerosis"},{"key":"10.1016\/j.phymed.2024.155505_bib0026","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12944-021-01431-x","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis","volume":"20","author":"Feder","year":"2021","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.phymed.2024.155505_bib0027","first-page":"19","article-title":"Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis","volume":"85","author":"Go","year":"2012","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029216","article-title":"Long-Term efficacy, safety, and tolerability of alirocumab in 8242 Patients Eligible for 3 to 5 years of placebo-controlled observation in the ODYSSEY OUTCOMES Trial","volume":"12","author":"Goodman","year":"2023","journal-title":"J. Am. Heart. Assoc."},{"key":"10.1016\/j.phymed.2024.155505_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202200139","article-title":"Micellar curcumin: pharmacokinetics and effects on inflammation markers and PCSK-9 concentrations in healthy subjects in a double-blind, randomized, active-controlled, crossover trial","volume":"66","author":"Grafeneder","year":"2022","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/liv.14711","article-title":"PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD","volume":"41","author":"Grimaudo","year":"2021","journal-title":"Liver. Int."},{"key":"10.1016\/j.phymed.2024.155505_bib0031","doi-asserted-by":"crossref","first-page":"80826","DOI":"10.18632\/oncotarget.20590","article-title":"Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression in vitro and in vivo","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget.Oncotarget."},{"key":"10.1016\/j.phymed.2024.155505_bib0032","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3892\/etm.2016.3400","article-title":"Tanshinone IIA protects H9c2 cells from oxidative stress-induced cell death via microRNA-133 upregulation and Akt activation","volume":"12","author":"Gu","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0033","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.actbio.2023.10.038","article-title":"Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease","volume":"174","author":"He","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.phymed.2024.155505_bib0034","first-page":"131","article-title":"Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis","author":"He","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phymed.2024.155505_bib0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/CIRCRESAHA.116.304637","article-title":"Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein","volume":"116","author":"Hooper","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0036","doi-asserted-by":"crossref","first-page":"12027","DOI":"10.1073\/pnas.1534923100","article-title":"Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes","volume":"100","author":"Horton","year":"2003","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"key":"10.1016\/j.phymed.2024.155505_bib0037","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00228-013-1537-1","article-title":"Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome","volume":"69","author":"Hou","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0038","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1177\/0300060519859750","article-title":"Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4","volume":"47","author":"Huang","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109258","article-title":"Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression","volume":"118","author":"Huang","year":"2019","journal-title":"Biomed. PharmacOther"},{"key":"10.1016\/j.phymed.2024.155505_bib0040","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2174\/0929867328666211108110025","article-title":"Tanshinone IIA: pharmacology, total synthesis, and progress in structure-modifications","volume":"29","author":"Huang","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0041","doi-asserted-by":"crossref","first-page":"11944","DOI":"10.1021\/acs.jafc.2c02681","article-title":"Chemical characterization and atherosclerosis alleviation effects of gypenosides from gynostemma pentaphyllum through ameliorating endothelial dysfunction via the PCSK9\/LOX-1 Pathway","volume":"70","author":"Huang","year":"2022","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/foods10020408","article-title":"The Cholesterol-Lowering Effect of Capsella Bursa-Pastoris Is Mediated via SREBP2 and HNF-1alpha-Regulated PCSK9 Inhibition in Obese Mice and HepG2 Cells","volume":"10","author":"Hwang","year":"2021","journal-title":"Foods."},{"key":"10.1016\/j.phymed.2024.155505_bib0043","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/hep4.1858","article-title":"Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: role of Cholesterol","volume":"6","author":"Ioannou","year":"2022","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.phymed.2024.155505_bib0044","first-page":"284","article-title":"Hepatic Alarmins and Mitochondrial Dysfunction under Residual Hyperlipidemic Stress Lead to Irreversible NAFLD","volume":"11","author":"Ivan","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.phymed.2024.155505_bib0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.abb.2016.01.001","article-title":"Tanshinone IIA affects the HDL subfractions distribution not serum lipid levels: involving in intake and efflux of cholesterol","volume":"592","author":"Jia","year":"2016","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.phymed.2024.155505_bib0046","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejphar.2019.05.019","article-title":"Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor alpha-mediated pathway in L02 cells","volume":"855","author":"Jing","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0047","first-page":"211","article-title":"Resveratrol protects against postmenopausal atherosclerosis progression through reducing PCSK9 expression via the regulation of the ER?-mediated signaling pathway","author":"Jing","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18105227","article-title":"Non-Alcoholic Fatty Liver Disease: metabolic, Genetic, Epigenetic and Environmental Risk Factors","volume":"18","author":"Juanola","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.phymed.2024.155505_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105205","article-title":"Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition","volume":"161","author":"Kim","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0050","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1248\/bpb.b14-00524","article-title":"Pharmacokinetics, tissue distribution, and tentative metabolite identification of sauchinone in mice by microsampling and HPLC-MS\/MS methods","volume":"38","author":"Kim","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.phymed.2024.155505_bib0051","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.phymed.2024.155505_bib0052","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jacl.2022.07.010","article-title":"Familial hypobetalipoproteinemia caused by homozygous loss-of-function mutations in PCSK9: a case report","volume":"16","author":"Kudo","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phymed.2024.155505_bib0053","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0021-5198(19)31702-0","article-title":"Pharmacological investigations of berberine sulphate","volume":"22","author":"Kulkarni","year":"1972","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0054","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/jat\/29.7.755","article-title":"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba","volume":"29","author":"Kupiec","year":"2005","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.phymed.2024.155505_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27020434","article-title":"PCSK9 as a target for development of a new generation of hypolipidemic drugs","volume":"27","author":"Kuzmich","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.phymed.2024.155505_bib0056","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phymed.2024.155505_bib0057","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89729","article-title":"E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver","volume":"2","author":"Lai","year":"2017","journal-title":"JCI. Insight."},{"key":"10.1016\/j.phymed.2024.155505_bib0058","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phymed.2024.155505_bib0059","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0060","article-title":"Trans-Epithelial Transport, Metabolism, and Biological Activity Assessment of the Multi-Target Lupin Peptide LILPKHSDAD (P5) and Its Metabolite LPKHSDAD (P5-Met)","volume":"13","author":"Lammi","year":"2021","journal-title":"Nutrients.Nutrients."},{"key":"10.1016\/j.phymed.2024.155505_bib0061","article-title":"Computational design and biological evaluation of analogs of lupin peptide P5 Endowed with Dual PCSK9\/HMG-CoAR Inhibiting Activity","volume":"14","author":"Lammi","year":"2022","journal-title":"Pharmaceutics.Pharmaceutics."},{"key":"10.1016\/j.phymed.2024.155505_bib0062","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jff.2016.02.042","article-title":"Lupin protein exerts cholesterol-lowering effects targeting PCSK9: from clinical evidences to elucidation of the in vitromolecular mechanism using HepG2 cells","volume":"23","author":"Lammi","year":"2016","journal-title":"J. Funct. Foods."},{"key":"10.1016\/j.phymed.2024.155505_bib0063","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jhepr.2019.10.009","article-title":"Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice","volume":"1","author":"Lebeau","year":"2019","journal-title":"JHEP. Rep."},{"key":"10.1016\/j.phymed.2024.155505_bib0064","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1074\/jbc.RA119.008094","article-title":"Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice","volume":"294","author":"Lebeau","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0065","first-page":"131","article-title":"The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury","author":"Lebeau","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phymed.2024.155505_bib0066","doi-asserted-by":"crossref","first-page":"17167","DOI":"10.1038\/s41598-019-53603-6","article-title":"PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phymed.2024.155505_bib0067","doi-asserted-by":"crossref","first-page":"938","DOI":"10.15252\/msb.20177703","article-title":"Network analyses identify liver-specific targets for treating liver diseases","volume":"13","author":"Lee","year":"2017","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.phymed.2024.155505_bib0068","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.fct.2008.01.008","article-title":"Warfarin overdose due to the possible effects of Lycium barbarumL","volume":"46","author":"Leung","year":"2008","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.phymed.2024.155505_bib0069","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bcp.13158","article-title":"Adverse events associated with interactions with dietary and herbal supplements among inpatients","volume":"83","author":"Levy","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0070","doi-asserted-by":"crossref","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","article-title":"Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine","volume":"284","author":"Li","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0071","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.2174\/1568026619666191114104718","article-title":"Medicinal value and potential therapeutic mechanisms of Gynostemma pentaphyllum (Thunb.) makino and its derivatives: an overview","volume":"19","author":"Li","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0072","first-page":"799","article-title":"Quercetin protects against ox\u2011LDL\u2011induced injury via regulation of ABCAl, LXR\u2011alpha and PCSK9 in RAW264.7 macrophages","volume":"18","author":"Li","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.phymed.2024.155505_bib0073","article-title":"PCSK9 Inhibition: from Current Advances to Evolving Future","volume":"11","author":"Liu","year":"2022","journal-title":"CellsCells"},{"key":"10.1016\/j.phymed.2024.155505_bib0074","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11655-014-1775-1","article-title":"Inhibition of proprotein convertase subtilisin\/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia","volume":"21","author":"Liu","year":"2015","journal-title":"Chin. J. Integr. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0075","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1177\/09603271211030558","article-title":"Quercetin inhibited the proliferation and invasion of hepatoblastoma cells through facilitating SIRT6-medicated FZD4 silence","volume":"40","author":"Liu","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.phymed.2024.155505_bib0076","first-page":"23","article-title":"Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder","author":"Lohoff","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phymed.2024.155505_bib0077","doi-asserted-by":"crossref","first-page":"519","DOI":"10.11569\/wcjd.v28.i13.519","article-title":"Ginkgolide B ameliorates high-fat diet-induced hepatic steatosis and inflammation in mice","volume":"28","author":"Long","year":"2020","journal-title":"World Chin. J. Digestol."},{"key":"10.1016\/j.phymed.2024.155505_bib0078","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.numecd.2019.06.001","article-title":"Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake","volume":"29","author":"Lupo","year":"2019","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.phymed.2024.155505_bib0079","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.21037\/atm-20-8106","article-title":"Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-\/-) mice by down-regulating PCSK9 via ERK1\/2 pathway","volume":"9","author":"Ma","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0080","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ajpath.2021.04.016","article-title":"Proprotein convertase subtilisin\/kexin type 9: a view beyond the canonical cholesterol-lowering impact","volume":"191","author":"Macchi","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phymed.2024.155505_bib0081","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/1547691X.2015.1058306","article-title":"Immunotoxicity induced in mice by subacute exposure to berberine","volume":"13","author":"Mahmoudi","year":"2016","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.phymed.2024.155505_bib0082","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12291-019-00858-5","article-title":"Anti-atherosclerotic and anti-inflammatory effects of curcumin on hypercholesterolemic male rabbits","volume":"36","author":"Majeed","year":"2021","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.phymed.2024.155505_bib0083","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","article-title":"Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice","volume":"44","author":"Maxwell","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0084","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201700729","article-title":"Mice Fed a high-cholesterol diet supplemented with quercetin-3-glucoside show attenuated hyperlipidemia and hyperinsulinemia associated with differential regulation of PCSK9 and LDLR in their Liver and Pancreas","volume":"62","author":"Mbikay","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0085","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.fob.2014.08.003","article-title":"Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin\/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture","volume":"4","author":"Mbikay","year":"2014","journal-title":"FEBS Open Bio."},{"key":"10.1016\/j.phymed.2024.155505_bib0086","first-page":"155","article-title":"Lipoprotein(a) catabolism: a case of multiple receptors","volume":"51","author":"McCormick","year":"2019","journal-title":"Pathology.Pathology."},{"key":"10.1016\/j.phymed.2024.155505_bib0087","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/hep4.1830","article-title":"Low Lipoprotein(a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease","volume":"6","author":"Meroni","year":"2022","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.phymed.2024.155505_bib0088","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jcs.2013.01.013","article-title":"Lunasin in cereal seeds: what is the origin?","volume":"57","author":"Mitchell","year":"2013","journal-title":"J. Cereal. Sci."},{"key":"10.1016\/j.phymed.2024.155505_bib0089","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/17512433.2022.2132229","article-title":"The role of PCSK9 in NAFLD\/NASH and therapeutic implications of PCSK9 inhibition","volume":"15","author":"Momtazi-Borojeni","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0090","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/ptr.4646","article-title":"Quercetin up-regulates LDL receptor expression in HepG2 cells","volume":"26","author":"Moon","year":"2012","journal-title":"PhytOther Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0091","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.transproceed.2016.11.029","article-title":"Acute calcineurin inhibitor nephrotoxicity secondary to turmeric intake: a case report","volume":"49","author":"Nayeri","year":"2017","journal-title":"TransPlant Proc."},{"key":"10.1016\/j.phymed.2024.155505_bib0092","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/cvr\/cvy144","article-title":"Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?","volume":"114","author":"Noto","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0093","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-Term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","journal-title":"CirculationCirculation"},{"key":"10.1016\/j.phymed.2024.155505_bib0094","first-page":"147","article-title":"Alcoholic liver disease: pathogenesis and current management","volume":"38","author":"Osna","year":"2017","journal-title":"Alcohol Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0095","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/FJC.0000000000000406","article-title":"Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"68","author":"Panahi","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0096","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacl.2014.12.006","article-title":"Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials","volume":"9","author":"Panta","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phymed.2024.155505_bib0097","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clinbiochem.2020.01.003","article-title":"Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis","volume":"77","author":"Paquette","year":"2020","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.phymed.2024.155505_bib0098","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bcp.14943","article-title":"Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis","volume":"88","author":"Pastori","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0099","article-title":"Evaluation of the multifunctionality of soybean proteins and peptides in immune cell models","volume":"15","author":"Paterson","year":"2023","journal-title":"Nutrients.Nutrients."},{"key":"10.1016\/j.phymed.2024.155505_bib0100","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1021\/acs.jafc.7b02088","article-title":"Chemical constituents with proprotein convertase subtilisin\/Kexin Type 9 mRNA Expression inhibitory activity from dried immature morus alba Fruits","volume":"65","author":"Pel","year":"2017","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0101","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jfda.2017.10.008","article-title":"Mulberry Leaf Extracts prevent obesity-induced NAFLD with regulating adipocytokines, inflammation and oxidative stress","volume":"26","author":"Peng","year":"2018","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.phymed.2024.155505_bib0102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12944-021-01610-w","article-title":"NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study","volume":"21","author":"Peng","year":"2022","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.phymed.2024.155505_bib0103","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mrrev.2011.11.001","article-title":"Biological activity of piceatannol: leaving the shadow of resveratrol","volume":"750","author":"Piotrowska","year":"2012","journal-title":"Mutat. Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0104","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0105","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","article-title":"Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route","volume":"284","author":"Poirier","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0106","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s12272-012-0715-5","article-title":"Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats","volume":"35","author":"Qin","year":"2012","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0107","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0108","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.taap.2006.09.005","article-title":"Ginkgolide A contributes to the potentiation of acetaminophen toxicity by Ginkgo biloba extract in primary cultures of rat hepatocytes","volume":"217","author":"Rajaraman","year":"2006","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0109","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.113.006720","article-title":"Proprotein Convertase subtilisin Kexin Type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms","volume":"130","author":"Rashid","year":"2014","journal-title":"CirculationCirculation"},{"key":"10.1016\/j.phymed.2024.155505_bib0110","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0111","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 trials of inclisiran in patients with elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0112","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2024.155505_bib0113","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1002\/j.1875-9114.2012.01018.x","article-title":"Probable interaction between Lycium barbarum (Goji) and Warfarin","volume":"32","author":"Rivera","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phymed.2024.155505_bib0114","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and Safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.5844","article-title":"Association of high-intensity binge drinking with lipid and liver function enzyme levels","volume":"2","author":"Rosoff","year":"2019","journal-title":"Jama Network Open"},{"key":"10.1016\/j.phymed.2024.155505_bib0116","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phymed.2024.155505_bib0117","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24071297","article-title":"Resveratrol and quercetin administration improves antioxidant defenses and reduces fatty liver in metabolic syndrome rats","volume":"24","author":"Rubio-Ruiz","year":"2019","journal-title":"Molecules."},{"key":"10.1016\/j.phymed.2024.155505_bib0118","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"Ruscica","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0119","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","article-title":"Liver fat accumulation is associated with circulating PCSK9","volume":"48","author":"Ruscica","year":"2016","journal-title":"Ann. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0120","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0121","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0122","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1152\/physiolgenomics.00127.2009","article-title":"Transcriptional profiling reveals divergent roles of PPAR\u03b1 and PPAR\u03b2\/\u03b4 in regulation of gene expression in mouse liver","volume":"41","author":"Sanderson","year":"2010","journal-title":"Physiol. Genomics."},{"key":"10.1016\/j.phymed.2024.155505_bib0123","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1039\/D1FO03847H","article-title":"A Lupinus angustifolius protein hydrolysate exerts hypocholesterolemic effects in Western diet-fed ApoE(-\/-) mice through the modulation of LDLR and PCSK9 pathways","volume":"13","author":"Santos-Sanchez","year":"2022","journal-title":"Food Funct."},{"key":"10.1016\/j.phymed.2024.155505_bib0124","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0125","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0126","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.numecd.2020.11.009","article-title":"Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience","volume":"31","author":"Scicali","year":"2021","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.phymed.2024.155505_bib0127","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1503\/cmaj.051191","article-title":"Warfarin interaction with Matricaria chamomilla","volume":"174","author":"Segal","year":"2006","journal-title":"CMAJ."},{"key":"10.1016\/j.phymed.2024.155505_bib0128","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The Multifaceted Biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.phymed.2024.155505_bib0129","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.phymed.2024.155505_bib0130","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.932961","article-title":"A new potential strategy for acute non-alcoholic steatohepatitis (NASH)","volume":"22","author":"Sekhon","year":"2021","journal-title":"Am. J. Case Rep."},{"key":"10.1016\/j.phymed.2024.155505_bib0131","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5455\/aim.2017.25.169-174","article-title":"Therapeutic Effects of Curcumin on Ultrasonic Morphological Characteristics of Liver in Patients with Metabolic Syndrome","volume":"25","author":"Selmanovic","year":"2017","journal-title":"Acta Inform. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0132","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/10408398.2020.1731678","article-title":"Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9?","volume":"61","author":"Shafabakhsh","year":"2021","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.phymed.2024.155505_bib0133","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.4254\/wjh.v12.i12.1258","article-title":"Effects of proprotein convertase subtilisin\/kexin type-9 inhibitors on fatty liver","volume":"12","author":"Shafiq","year":"2020","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.phymed.2024.155505_bib0134","doi-asserted-by":"crossref","first-page":"281","DOI":"10.18632\/aging.100652","article-title":"Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease","volume":"6","author":"Sheedfar","year":"2014","journal-title":"Aging (Albany. NY)"},{"key":"10.1016\/j.phymed.2024.155505_bib0135","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1080\/13880209.2022.2126503","article-title":"Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4\/nuclear factor kappa B pathways","volume":"60","author":"Shen","year":"2022","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.phymed.2024.155505_bib0136","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ajg.2017.469","article-title":"ACG Clinical Guideline: alcoholic liver disease","volume":"113","author":"Singal","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phymed.2024.155505_bib0137","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.3748\/wjg.v23.i36.6549","article-title":"Treatment options for alcoholic and non-alcoholic fatty liver disease: a review","volume":"23","author":"Singh","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phymed.2024.155505_bib0138","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jn\/134.1.18","article-title":"Proteins of white lupin seed, a naturally isoflavone-poor legume, reduce cholesterolemia in rats and increase LDL receptor activity in HepG2 cells","volume":"134","author":"Sirtori","year":"2004","journal-title":"J. Nutr."},{"key":"10.1016\/j.phymed.2024.155505_bib0139","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1017\/S0007114511004120","article-title":"Hypocholesterolaemic effects of lupin protein and pea protein\/fibre combinations in moderately hypercholesterolaemic individuals","volume":"107","author":"Sirtori","year":"2012","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.phymed.2024.155505_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111137","article-title":"Salidroside simultaneously reduces de novo lipogenesis and cholesterol biosynthesis to attenuate atherosclerosis in mice","volume":"134","author":"Song","year":"2021","journal-title":"Biomed. PharmacOther."},{"key":"10.1016\/j.phymed.2024.155505_bib0141","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2169\/internalmedicine.3737-19","article-title":"A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene","volume":"59","author":"Tada","year":"2020","journal-title":"Intern. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0142","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/mnfr.201400366","article-title":"Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells","volume":"58","author":"Tai","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0143","doi-asserted-by":"crossref","first-page":"e77969","DOI":"10.1371\/journal.pone.0077969","article-title":"Tissue distribution of berberine and its metabolites after oral administration in rats","volume":"8","author":"Tan","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phymed.2024.155505_bib0144","doi-asserted-by":"crossref","first-page":"29252","DOI":"10.1074\/jbc.M113.481473","article-title":"FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin\/kexin type 9 (Pcsk9) gene expression","volume":"288","author":"Tao","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0145","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.atherosclerosis.2007.05.003","article-title":"Molecular diagnosis of hypobetalipoproteinemia: an ENID review","volume":"195","author":"Tarugi","year":"2007","journal-title":"AtherosclerosisAtherosclerosis"},{"key":"10.1016\/j.phymed.2024.155505_bib0146","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacl.2019.12.003","article-title":"Impact of proprotein convertase subtilisin\/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects","volume":"14","author":"Taskinen","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phymed.2024.155505_bib0147","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/ATVBAHA.120.315446","article-title":"Effects of evolocumab on the postprandial kinetics of Apo (Apolipoprotein) B100-and B48-containing lipoproteins in subjects with type 2 diabetes","volume":"41","author":"Taskinen","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phymed.2024.155505_bib0148","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.21873\/anticanres.12729","article-title":"Global Liver gene expression analysis on a murine hepatic steatosis model treated with mulberry (Morus alba L.) Leaf Powder","volume":"38","author":"Uchiyama","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phymed.2024.155505_bib0149","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jacl.2020.12.010","article-title":"Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD","volume":"15","author":"Vilar-Gomez","year":"2021","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phymed.2024.155505_bib0150","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 modulates the secretion but not the cellular Uptake of Lipoprotein(a) Ex Vivo: an effect blunted by alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC. Basic Transl. Sci."},{"key":"10.1016\/j.phymed.2024.155505_bib0151","article-title":"Ginkgolide B mediated alleviation of inflammatory cascades and altered lipid metabolism in HUVECs via Targeting PCSK-9 expression and functionality","volume":"2019","author":"Wang","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.phymed.2024.155505_bib0152","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153688","article-title":"Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression","volume":"91","author":"Wang","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phymed.2024.155505_bib0153","article-title":"Evaluation of Tanshinone IIA developmental toxicity in zebrafish embryos","volume":"22","author":"Wang","year":"2017","journal-title":"Molecules."},{"key":"10.1016\/j.phymed.2024.155505_bib0154","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/FJC.0000000000001053","article-title":"Inclisiran: a novel agent for lowering apolipoprotein B-containing lipoproteins","volume":"78","author":"Warden","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2018.09.008","article-title":"Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population","volume":"278","author":"Wargny","year":"2018","journal-title":"AtherosclerosisAtherosclerosis"},{"key":"10.1016\/j.phymed.2024.155505_bib0156","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOL.0000000000000663","article-title":"Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease","volume":"31","author":"Welty","year":"2020","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.phymed.2024.155505_bib0157","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1039\/D3OB00225J","article-title":"Chemical constituents from Morus alba with proprotein convertase subtilisin\/kexin type 9 expression and secretion inhibitory activity","volume":"21","author":"Won","year":"2023","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.phymed.2024.155505_bib0158","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/00029330-200705020-00013","article-title":"Pharmacological action and mechanisms of ginkgolide B","volume":"120","author":"Xia","year":"2007","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.phymed.2024.155505_bib0159","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.764038","article-title":"Regulation of PCSK9 expression and function: mechanisms and therapeutic implications","volume":"8","author":"Xia","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbrc.2022.07.031","article-title":"A novel mouse model of diabetes, atherosclerosis and fatty liver disease using an AAV8-PCSK9-D377Y injection and dietary manipulation in db\/db mice","volume":"622","author":"Xu","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phymed.2024.155505_bib0161","first-page":"4639","article-title":"Effect of tanshinone IIA on oxidative stress and apoptosis in a rat model of fatty liver","volume":"14","author":"Yang","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.phymed.2024.155505_bib0163","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.crfs.2020.03.008","article-title":"Piceatannol attenuates fat accumulation and oxidative stress in steatosis-induced HepG2 cells","volume":"3","author":"Yang","year":"2020","journal-title":"Curr. Res. Food Sci."},{"key":"10.1016\/j.phymed.2024.155505_bib0164","article-title":"Mulberry Leaf (Morus alba L.) extracts and its chlorogenic acid isomer component improve glucolipotoxicity-induced hepatic lipid accumulation via downregulating mir-34a and decreased inflammation","volume":"14","author":"Yang","year":"2022","journal-title":"Nutrients.Nutrients."},{"key":"10.1016\/j.phymed.2024.155505_bib0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0378-8741(01)00387-7","article-title":"Berberis crataegina DC. root exhibits potent anti-inflammatory, analgesic and febrifuge effects in mice and rats","volume":"79","author":"Yesilada","year":"2002","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0166","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25163737","article-title":"Ten New Dammarane-Type Saponins with Hypolipidemia Activity from a Functional Herbal Tea-Gynostemma pentaphyllum","volume":"25","author":"Yin","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.phymed.2024.155505_bib0167","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - A global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2024.155505_bib0168","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/20009666.2019.1710952","article-title":"Proprotein convertase subtilisin\/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis","volume":"10","author":"Zafar","year":"2020","journal-title":"J. Commun. Hosp. Intern. Med. Perspect."},{"key":"10.1016\/j.phymed.2024.155505_bib0169","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2024.155505_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175195","article-title":"Curcumin nicotinate decreases serum LDL cholesterol through LDL receptor-mediated mechanism","volume":"931","author":"Zhang","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phymed.2024.155505_bib0171","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.toxrep.2015.08.011","article-title":"Bleeding due to a probable interaction between warfarin and Gouqizi (Lycium Barbarum L.)","volume":"2","author":"Zhang","year":"2015","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.phymed.2024.155505_bib0172","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1038\/s41598-022-09610-1","article-title":"Metformin Ameliorates hepatic steatosis induced by olanzapine through inhibiting LXRalpha\/PCSK9 pathway","volume":"12","author":"Zhu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phymed.2024.155505_bib0173","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21101336","article-title":"The potential mechanisms of berberine in the treatment of nonalcoholic fatty liver disease","volume":"21","author":"Zhu","year":"2016","journal-title":"Molecules."},{"key":"10.1016\/j.phymed.2024.155505_bib0174","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/hep4.1042","article-title":"CAT-2003: a novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden Mice","volume":"1","author":"Zimmer","year":"2017","journal-title":"Hepatol. Commun."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711324001697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711324001697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T15:22:30Z","timestamp":1724080950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711324001697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":173,"alternative-id":["S0944711324001697"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2024.155505","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A promising therapy for fatty liver disease: PCSK9 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2024.155505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155505"}}